# 此超級綜合評等是基於以下評等的加權平均排名結果。

*biotech · news · 2026-05-29 · MarketScreener*

## Key points

- Trader 超級評等使用加權平均，強調 4 個月的每股盈餘修正成分。
- Investor 超級綜合評等獨特地納入 1 年的每股盈餘修正因素進行分析。
- Global 評等僅在公司至少擁有五項輸入評等中的四項時適用。
- Quality 評等要求至少涵蓋三項指定指標中的兩項才能計算。

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/innovent-biologics-enters-licensing-agreement-with-pfizer-for-12-oncology-programs-ce7f5ddad08ff526)

---

Canonical: https://newsio.io/zh-TW/n/f98930b7-fea1-44f6-aba3-a7ae1771db03/
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works